

PATENT LICENSE AGREEMENT

This PATENT LICENSE AGREEMENT (this “Agreement”) is entered into by and between Greenthread, LLC, a Texas limited liability company with a principal place of business at 7424 Mason Dells Drive, Dallas, TX 75230-3244 (“Licensor”), and RPX Corporation, a Delaware corporation with a principal place of business at Four Embarcadero Center, Suite 4000, San Francisco, CA 94111 (“RPX”), on the date when this Agreement has been executed by both Licensor and RPX (the “Effective Date”). Each of RPX and Licensor is a “Party”, and collectively, are referenced as the “Parties”.

WHEREAS, Licensor is the sole and exclusive owner of, and has the right to license in the United States and throughout the world, the Patents (as defined below);

WHEREAS, RPX desires to acquire from Licensor a Patent License (as defined below), including the right to grant to RPX Licensees (as defined below) a sublicense of the same scope and duration as the Patent License, provided that the preconditions to the granting of such rights as described herein are met;

WHEREAS, Licensor is willing to grant to RPX a Patent License, including the right to grant to RPX Licensees a sublicense of the same scope and duration as the Patent License, provided that the preconditions to the granting of such rights as described herein are met; and

NOW, THEREFORE, in consideration of the premises and covenants herein contained, RPX and Licensor agree as follows:

Definitions

As used herein, the following terms shall have the following meanings:

“Affiliate(s)” of an Entity shall mean any and all Entities, now or in the future, and for so long as the Control exists, that are Controlled, directly or indirectly, by the Entity.

“Agreement” shall have the meaning ascribed to it in the preamble.

“Bankruptcy Code” shall have the meaning ascribed to it in Section 5.10.

“Claims” shall mean any and all claims, counterclaims, third-party claims, contribution claims, indemnity claims, demands, actions, liabilities, damages, losses, causes of action, and all other claims of every kind and nature in law or equity, whether arising under state, federal, international or other law, which arise from or relate to in any way the Patents, or which are (currently or in the future) or were asserted in, could have been asserted in, or which arise from the same transactions or occurrences as those claims that are (currently or in the future) or were asserted in any Licensor Litigations with respect to the Patents, whether such claims are absolute or contingent, in tort, contract or otherwise, direct or indirect, present or future, known or unknown.

“Combined Licensed Product and Service” shall mean any past, present or future combination or use, whether by an RPX Licensee, an RPX Licensee Affiliate, or a third party, of

a Licensed Product and Service with any other product, service, technology, or material, only if such Licensed Product and Service or a portion thereof provided by or on behalf of an RPX Licensee or an RPX Licensee Affiliate satisfies, in whole or in part, an element or a step of a claim in any Patent. For clarity, a Combined Licensed Product and Service will not include any product, service, technology or material of any Entity that is not an RPX Licensee or RPX Licensee Affiliate that independently satisfies all of the elements of a claim in any Patent, provided that Licensor has not and does not allege that any Licensed Product and Service of an RPX Licensee or RPX Licensee Affiliate satisfies, in whole or in part, an element or step of a claim in any Patent.

“Control” shall mean the legal, beneficial, and/or equitable ownership (directly or indirectly) of more than fifty percent (50%) of (i) the voting power representing the right to vote for directors or other managing authority, (ii) equity ownership interest in an Entity, or (iii) other ownership interest in an Entity.

“Covered Third Party” shall have the meaning ascribed to it in Section 1.2(c).

“Effective Date” shall have the meaning ascribed to it in the preamble.

“Entity” shall mean a corporation, association, partnership, business trust, joint venture, limited liability company, proprietorship, unincorporated association, individual or other entity that can exercise independent legal standing.

“Form of Dismissal” shall mean the form notice of dismissal in Exhibit D attached hereto.

“Initial Licensee” shall mean each Entity identified in Exhibit A, each such Entity’s Affiliates, and any business unit or division that such Entity may divest.

“License Fee” shall have the meaning ascribed to it in Section 1.1.

“Licensed Product and Service” shall mean any past, present or future product, service, software, firmware, macros, technology, integrated circuits, systems, IP blocks, cores, cells, designs, specifications, or material (including any components, devices, data, media, or any other portions thereof), at any time, made, have made, used, purchased, provided, hosted, sold, leased, licensed, distributed, transmitted, exported, imported or offered for sale, lease, or import or otherwise exploited or disposed of by or on behalf of an RPX Licensee or an RPX Licensee Affiliate (along with any designs, methods, or processes for the manufacture or operation thereof) alone or in combination (including as a Combined Licensed Product and Service) with other products, software, technology, materials and services, the manufacture, use, purchase, provision, hosting, sale, lease, license, distribution, transmittal, export, import (or offer for sale, lease or import) of which would result in infringement (direct, indirect, or otherwise) of one or more Patents, irrespective of whether the product, service, software, firmware, macros, technology, integrated circuits, systems, IP blocks, cores, cells, designs, specifications, or material (including any components, devices, data, media, or any other portions thereof) were or had been made, used, purchased, provided, hosted, sold, leased, licensed, distributed, transmitted, exported, imported or offered for sale, lease, or import in the United States.

“Licensee Nullity Proceedings” shall mean any and all *inter partes reviews* (or other proceedings before the PTO), and nullity actions and opposition proceedings pending in any court or tribunal in the United States or any foreign country, filed prior to the Effective Date relating to any Patent initiated by any RPX Licensee against Licensor, as specifically set forth on Exhibit E hereto.

“Licensor” shall have the meaning ascribed to it in the preamble.

“Licensor Litigations” shall mean any and all lawsuits relating to any Patent filed at any time by Licensor or its Affiliates in any state or federal court in the United States, in any court or tribunal in any foreign country, or before the United States International Trade Commission, including those lawsuits and proceedings specifically listed in Exhibit E. Any one of the Licensor Litigations is a “Licensor Litigation”.

“Licensor Litigation Defendants” shall mean the parties adverse to Licensor or its Affiliates in any Licensor Litigation. Any one of the Licensor Litigation Defendants is a “Licensor Litigation Defendant”.

“Party” and “Parties” shall have the meanings ascribed to them in the preamble.

“Patent License” shall mean a perpetual, royalty-free, fully paid-up, irrevocable, non-exclusive worldwide license under the Patents to make, have made, use, have used, sell, lease, have leased, offer for sale, have offered for sale, have sold, copy, develop, have developed, operate, market, have marketed, import, have imported, own, order, design, purchase, practice, obtain, keep, acquire, receive, build, deliver, host, distribute, have distributed, provide, supply, export, have exported, practice all methods and processes, and otherwise exploit or dispose of any Licensed Product and Service and/or Combined Licensed Product and Service, and for which the term of such license under the Patents shall extend to the expiration of each patent comprising the Patents.

“Patents” shall mean: (i) the patents and patent applications identified on Exhibit B, together with any and all patents and patent applications that are owned, controlled or licensable as of the Effective Date or later by Licensor and/or its Affiliates, and any and all foreign counterparts of any of the foregoing; (ii) any and all patents that have issued or may issue from any of the patents or patent applications described in (i) of this definition; (iii) any and all patents and patent applications that, in whole or in part, claim priority to (directly or indirectly), or the benefit of the filing date of, any of the patents or patent applications described in (i) or (ii) of this definition, including any and all child, continuation, continuation-in-part, continuing prosecution, divisional, provisional, non-provisional, reissue, reexamination, substitution, post-issuance trial certificate, extension and counterpart patents and patent applications of any of the patents or patents applications described in (i) or (ii) of this definition; (iv) any and all patents and patent applications from which any of the patents or patent applications described in (i), (ii) or (iii) of this definition, in whole or in part, claim the benefit of priority (directly or indirectly) or otherwise claim the benefit of the filing date, including any and all parent patents or patent applications of any of the patents or patent applications described in (i), (ii) or (iii) of this definition; and (v) any and all extensions or renewals of any of the patent or patent applications described in this

definition. Any one of the foregoing is a “Patent”. Licensor is not granting, and does not have any authority to grant, any rights, express or implied, to U.S. Patent Nos. 8,891,298; 9,196,385; 9,997,240; 10,950,300, or any patent claiming priority directly or indirectly from or through application in common with such patents (i.e. any parent or child of such patents); or any other patents or patent applications owned or Controlled by Vervain LLC (“Vervain Patents”), so long as the Vervain Patents are not owned, controlled, or licensable by Licensor and/or its Affiliates.

“PTO” shall mean the United States Patent & Trademark Office.

“Release and Dismissal Obligations” shall mean Licensor, on behalf of itself and its Affiliates, immediately (i) executing a written release agreement containing terms that are substantially similar in scope and effect as the Release Terms, and (ii) with respect to any Licensor Litigation Defendant, taking all actions and making all necessary filings to resolve all disputes with respect to such Licensor Litigation Defendant relating to or arising out of the Licensor Litigations, including without limitation executing and filing a dismissal “with prejudice” substantially similar in form and effect to the Form of Dismissal (or, with respect to any Licensor Litigation in a non-U.S. jurisdiction, a dismissal “with prejudice” in such form as is appropriate for the relevant jurisdiction).

“Release Terms” shall mean the terms and conditions in Exhibit C attached hereto.

“RPX” shall have the meaning ascribed to it in the preamble.

“RPX Licensee” shall have the meaning ascribed to it in Section 1.2(a).

“Section 1542” shall have the meaning ascribed to it in Section 4.3(b).

“Underlying Claim” shall have the meaning ascribed to it in Section 4.2(b).

“Withholding Tax” shall mean any amount of tax assessment, levy or other charge to be deducted and withheld on behalf of, and to be paid to, a government which is based on the gross value of the payment and which is in lieu of an income tax.

Section 1. Fees, Patent License and CTSL

1.1 Fees. Within ten (10) business days following the Effective Date of this Agreement, RPX shall pay to Licensor the amount of Ten Million U.S. Dollars (US\$10,000,000) (the “License Fee”). Payments made under this Agreement shall be made via wire transfer, without deduction of taxes or banking fees of any kind, per the following wire account information:

Bank Name: Citibank, N.A.
Bank Address: 300 Crescent Court, Suite # 950 Dallas, TX 75201
Routing No: 113193532
Routing Beneficiary: McKool Smith PC IOLTA Trust Account
Beneficiary Acct. No.: 9792263923
Beneficiary Address: 300 Crescent Court, Suite # 950 Dallas, TX 75201

1.2 Patent License.

(a) Effective upon RPX's payment to Licensor of the License Fee, Licensor shall automatically be deemed to grant, and does hereby grant, to RPX the Patent License, which Patent License shall include the exclusive and irrevocable right of RPX to grant sublicenses under the Patent License to all Initial Licensees.

The Patent License shall also include the express right of RPX to release, on behalf of Licensor and its Affiliates, the foregoing sublicensees from all claims for damages for past, present and future infringement of the Patents. Any Entity that is granted a sublicense by RPX (directly or indirectly) in accordance with Section 1.2(a) shall be deemed an "RPX Licensee" for purposes of this Agreement.

(b) Effective upon RPX's payment to Licensor of the License Fee, Licensor shall immediately complete the Release and Dismissal Obligations with respect to any Initial Licensees and their Affiliates that are Licensor Litigation Defendants.

(c) The sublicense (and release) granted in accordance with Section 1.2(a) and Section 4.3 to any Entity under the Patent License shall be deemed to be a further sublicense (and release) to that Entity's Affiliates ("RPX Licensee Affiliates"), and such RPX Licensees' and RPX Licensee Affiliates' direct and indirect customers, have-made vendors, developers, distributors, dealers, suppliers, manufacturers, original equipment manufacturers (OEMs), original design manufacturers (ODMs), system integrators, other contractors, licensees, and users (including end users) solely to the extent such third parties make, have made, use, purchase, provide, host, sell, lease, distribute, supply, export, import, offer for sale, or otherwise exploit or dispose of any Licensed Product and Service and/or Combined Licensed Product and Service (each, a "Covered Third Party"). Each RPX Licensee shall have the right, consistent with this Section 1.2(c), to grant specific non-sublicensable, non-assignable sublicenses to its Covered Third Parties with respect to such RPX Licensee's or its Affiliates' Licensed Products and Services and/or Combined Licensed Product and Service.

(d) For clarity and without limiting anything herein, if an Entity becomes an "Affiliate" of an RPX Licensee after the Effective Date of this Agreement (a "Future Affiliate"), then the sublicenses, covenants and releases granted under this Agreement to such RPX Licensee shall extend to the acts of such Future Affiliate occurring prior to, as of, and following the date on which such Entity became a Future Affiliate.

(e) If RPX Licensee or any RPX Licensee Affiliates sells or transfers a portion of its assets or business, including through formation of a joint venture or sale of an entity (a "Spin-Off"), then RPX Licensee or RPX Licensee Affiliates shall have the right to grant a sublicense under the licenses, covenants and releases granted herein to such Spin-Off with respect to such assets or business provided, however, that any rights so sublicensed to any Spin-Off shall be limited to the business of the Spin-Off as of the date of the Spin-Off (and improvements and natural evolutions thereof) and shall not extend otherwise to any acquirer of such Spin-Off, the acquirer's Affiliates or any such acquirer's or such Affiliates' other businesses. This Agreement shall

otherwise remain in effect with respect to RPX Licensee, RPX Licensee Affiliates and the licenses, covenants and releases shall continue to apply to the business and assets retained or later acquired by RPX Licensee and RPX Licensee Affiliates in addition to those transferred to the Spin-Off.

1.3 Covenant To Sue Last.

(a) Effective upon RPX's payment to Licensor of the License Fee, Licensor, on behalf of itself, its Affiliates, and each of their respective successors and assigns, shall automatically be deemed to grant, and does hereby grant, to RPX the CTSL (as defined below), which CTSL shall include the irrevocable right of RPX to grant rights under the CTSL to Dell Technologies Inc., Dell Inc., each of their Affiliates, and any business unit or division that Dell Technologies Inc., Dell Inc., or their respective Affiliates may divest (collectively, "Grantee"). The CTSL shall mean: Licensor agrees, on behalf of itself and its Affiliates, and each of their respective successors and assigns, that it can sue Grantee (or any downstream customers of Grantee, based on any products and/or services of Grantee) for direct or indirect infringement (including, without limitation, inducement, or contributory infringement) under any of the Patents, only after Licensor has first fully pursued and exhausted any and all claims for infringement of the Patents (including any and all appeals and all available efforts to collect any judgment or settlement amount) against any and all other Entities. Licensor represents and warrants that, as of the Effective Date, at least one such other Entity exists against whom it has a claim for infringement of each Patent. Notwithstanding anything to the contrary, the existence and/or grant of the CTSL will not be used in connection with establishing or alleging against Grantee any claim of willful patent infringement.

(b) Effective upon RPX's payment to Licensor of the License Fee, Licensor shall immediately (i) execute in favor of Grantee a written agreement containing terms that are substantially similar in scope and effect as the CTSL Agreement in Exhibit F attached hereto, and (ii) take all actions and make all necessary filings to resolve all disputes with Grantee under any Licensor Litigation Defendant, including without limitation executing and filing a dismissal "without prejudice" substantially similar in form and effect to the form of dismissal in Exhibit G attached hereto (or, with respect to any Licensor Litigation in a non-U.S. jurisdiction, a dismissal "without prejudice" in such form as is appropriate for the relevant jurisdiction).

(c) For clarity and without limiting anything herein, if an Entity becomes an "Affiliate" of Grantee after the Effective Date of this Agreement, then the CTSL granted under this Agreement to such Grantee shall extend to the acts of such future Affiliate occurring prior to, as of, and following the date on which such Entity became a future Affiliate.

(d) If Grantee or any Grantee Affiliates sells or transfers a portion of its assets or business, including through formation of a joint venture or sale of an entity (a "Grantee Spin-Off"), then Grantee or Grantee Affiliates shall have the right to extend the CTSL granted herein to such Grantee Spin-Off with respect to such assets or business provided, however, that any CTSL to any Grantee Spin-Off shall be limited to the business of the Grantee Spin-Off as of the date of the Grantee Spin-Off and shall not extend otherwise to any acquirer of such Grantee Spin-Off, the acquirer's Affiliates or any such acquirer's or such Affiliates' other businesses. This Agreement shall otherwise remain in effect with respect to Grantee and Grantee Affiliates and the CTSL shall

continue to apply to the business and assets retained or later acquired by Grantee and Grantee Affiliates in addition to those transferred to the Grantee Spin-Off.

Section 2. Representations and Warranties

2.1 Representations and Warranties of Licensor. Licensor, on behalf of itself and its Affiliates, represents and warrants that, as of the Effective Date:

(a) it has all requisite legal right, power, and authority to execute and deliver all documents required to be executed (including this Agreement), and to perform all of its obligations under and grant all rights in accordance with this Agreement;

(b) it has good and marketable title to the Patents (including, without limitation, all right, title, and interest in the Patents and the right to sue for past, present and future infringements thereof); Licensor has the legal right to grant the CTSL granted in Section 1.3 as well as the Patent License and release set forth in Section 1.2 and Section 4.3, and it has accurate and complete copies of all agreements under which it obtained by assignment or otherwise such title to the Patents;

(c) the Patents are not subject to any licenses, covenants not to sue, liens, security interests, or other encumbrances that would impair the rights granted hereunder;

(d) the inventions and discoveries described in the Patents were made solely by the inventor(s) named in the Patents, and no other party has any inventorship rights with respect to any such inventions or to the Patents;

(e) it has not entered and shall not enter into any agreement that would materially impair or conflict with its obligations hereunder;

(f) there has been no previous sale, transfer, assignment or other grant of rights under the Patents or any other agreement by Licensor or any of its Affiliates that affects, in any manner, title to, or RPX's or any RPX Licensee's, RPX Licensee Affiliates, or any of the Covered Third Parties' enjoyment of, the Patents or the underlying inventions, including, but not limited to, an assignment of full or partial rights in or to one or more of the Patents, an exclusive license to one or more of the Patents, or a right or option to obtain an exclusive license;

(g) performance of this Agreement does not and will not conflict with or result in a breach of any agreement to which it is bound;

(h) other than as asserted in affirmative defenses, counterclaims, or otherwise in the Licensor Litigations, none of the inventors of the Patents nor their counsel: (i) intentionally failed to disclose any material, non-cumulative prior art references to the PTO or any foreign patent offices requiring such disclosure in connection with the prosecution of any Patents; (ii) made any material misstatements or misrepresentations to the PTO or any foreign patent offices in connection with the prosecution of any of the Patents; or (iii) engaged in any act or omission inconsistent with the duty of candor owed to the PTO or to any foreign patent offices;

(i) Licensor and its Affiliates do not own any right, title or interest in, or have exclusive license rights under, any patents or patent applications other than the Patents. To the extent that on the Effective Date, Licensor or its Affiliates own any right, title or interest in, has exclusive license rights under, or has the right to enforce or control, any patents or patent applications that are not expressly listed on Exhibit B, their omission from Exhibit B was inadvertent and such patents and patent applications were intended to be, and shall be treated as if they were, included on Exhibit B;

(j) neither Licensor nor any of its Affiliates has, in the twelve (12) month period prior to the Effective Date, divested (or otherwise assigned or transferred ownership or the right to enforce, license or control) any Patents, patents or patent applications to any Entity.

2.2 Representations and Warranties of RPX. RPX represents and warrants that it has all requisite legal right, power, and authority to execute, deliver, and perform this Agreement.

Section 3. Covenants of Licensor

In addition to and without limiting any other covenants contained in this Agreement, Licensor, on behalf of itself and its Affiliates, further covenants as follows:

(a) it will not, and will ensure that none of its Affiliates will, enter into any agreement that would materially impair or conflict with its obligations hereunder;

(b) in the event it or any of its Affiliates transfers, assigns or conveys any interest in and to the Patents to any Entity, it will obligate such Entity to agree in writing to: (i) abide by all covenants, releases, rights and obligations owed under this Agreement by Licensor or its Affiliates; (ii) take the Patents subject to the CTSL, Patent License, release and covenants granted by Licensor hereunder and subject to any rights granted by RPX in accordance with this Agreement, and (iii) impose the obligations of this section in writing upon any subsequent assignees or transferees such that this section travels with and survives any transfer and/or assignment of the Patents;

(c) it shall pay all taxes (including, without limitation, sales and value added taxes) imposed on Licensor by the national government, and any state, local or other political subdivision thereof, of any country in which Licensor is subject to taxation, as the result of RPX's furnishing consideration hereunder;

(d) as of and following the date that RPX has paid the License Fee, neither Licensor nor any of its Affiliates will sue or threaten to sue (or instruct, encourage, or aid a third party to sue or threaten to sue) RPX, any RPX Affiliate, any RPX Licensee, or any RPX Licensee Affiliate for direct or indirect infringement (including, without limitation, inducement, or contributory infringement) under any Patent, and neither Licensor nor any of its Affiliates will sue or threaten to sue (or instruct, encourage, or aid a third party to sue or threaten to sue) any Covered Third Party for direct or indirect infringement (including, without limitation, inducement, or contributory infringement) under any Patent with respect to any Licensed Product and Service and/or Combined

Licensed Product and Service. As of and following the date that RPX has paid the License Fee, neither Licensor nor any of its Affiliates will allege that any product, software, technology, material and/or services of any RPX Licensee or any RPX Licensee Affiliate satisfies an element or step of a claim in any Patent against any Entity;

(e) as of and following the date that RPX has paid the License Fee, in the event that RPX or any RPX Licensee or Grantee provides written notice to Licensor that Licensor or its Affiliates have sued or threatened to sue (or instructed, encouraged, or aided a third party to sue or threaten to sue) any Entity in violation of Section 3(d) or Section 1.3, Licensor will immediately cease, and will cause its Affiliates to immediately cease, making any such threats and promptly dismiss (with prejudice, with respect to Section 3(d), and without prejudice with respect to Section 1.3), any such lawsuit (or other adversarial proceeding), and, to the extent Licensor or its Affiliates fails to take such action within five (5) days following such written notice, Licensor will promptly reimburse RPX, such RPX Licensee, RPX Licensee Affiliates, Grantee, Grantee Affiliate, and such damaged Entity (including but not limited to Covered Third Parties), as applicable, for any reasonable costs (including reasonable attorney fees) incurred as a result of such threat or lawsuit; and

(f) after the Effective Date, neither Licensor nor its Affiliates shall acquire any right, title or interest in, or exclusive license rights under, or the right to enforce or control, any patents or patent applications other than the Patents. To the extent that, after the Effective Date, Licensor or its Affiliates owns any right, title or interest in, or has exclusive license rights (or the right to grant rights), or has the right to enforce or control, under, any patents or patent applications that are not expressly listed on Exhibit B, then (i) such patents and patent applications are intended to be, and shall be treated as if they are, included on Exhibit B; and (ii) all rights, licenses, releases, waivers, representations, covenants, immunities and terms granted under this Agreement with respect to such patents and patent applications shall become effective immediately as of the first date that each such patent or patent application becomes owned, controlled, or licensable by Licensor or its Affiliates.

Section 4. Disclaimers, Indemnification and Releases

4.1 Disclaimer. NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY EXCEPT AS EXPRESSLY SET FORTH IN SECTIONS 2 AND 3 ABOVE, AND EACH PARTY DISCLAIMS ALL IMPLIED WARRANTIES, INCLUDING, WITHOUT LIMITATION, THE IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. EXCEPT AS EXPRESSLY SET FORTH IN SECTIONS 2 AND 3, NEITHER PARTY GIVES THE OTHER PARTY ANY ASSURANCE:

(A) REGARDING THE PATENTABILITY OF ANY CLAIMED INVENTION IN, OR THE VALIDITY, OF ANY PATENT, OR

(B) THAT THE MANUFACTURE, USE, SALE, OFFERING FOR SALE, IMPORTATION, EXPORTATION, OR OTHER DISTRIBUTION OF ANY LICENSED PRODUCT AND SERVICE AND/OR COMBINED LICENSED PRODUCT AND SERVICE

DISCLOSED AND CLAIMED IN ANY PATENT BY ANY LICENSEE, SUBLICENSEE OR ANYONE ELSE WILL OR WILL NOT CONSTITUTE AN INFRINGEMENT OF SUCH RIGHTS OR ANY INTELLECTUAL PROPERTY RIGHTS OF ANY OTHER PERSONS OR ENTITIES.

4.2. Indemnification.

(a) Licensor shall defend, indemnify and hold harmless RPX and its Affiliates, and their directors, officers, agents and employees from and against any and all actual or pending claims, losses, expenses damages or other liabilities (including reasonable attorneys' fees), including those incurred in any dispute between the Parties, arising from Licensor's breach under this Section 4.2(a)), with any third party, or in any enforcement of this provision, arising out of, relating to, or based upon Licensor's or any of its Affiliates' material breach of any representation, warranty or covenant in this Agreement.

(b) In addition to any other remedies available to RPX, in the event RPX shall have a claim under Section 4.2(a), RPX shall promptly notify Licensor in writing of the claim, action, suit, proceeding or other circumstances giving rise to the claim for indemnification (collectively, the "Underlying Claim"); provided, however, that the failure to give such notice shall release Licensor of its indemnification obligations only to the extent that Licensor is prejudiced by such failure. Upon receipt of such notice of an Underlying Claim, Licensor may, by written notice to RPX delivered within thirty (30) business days of receiving such notice of the Underlying Claim, assume the sole defense and control of any third-party claim with its own counsel and at its own expense but shall allow RPX (or its applicable Affiliates) a reasonable opportunity to participate in the defense of such third-party claim with its own counsel and at its own expense. RPX (or its applicable Affiliates) may take any actions reasonably necessary to defend such third-party claim prior to the time that it receives a notice as contemplated by the preceding sentence. Licensor shall not settle any such claim other than for the payment of money without the prior written consent of RPX (or the applicable Affiliate), which consent shall not be unreasonably withheld or delayed. RPX will provide Licensor, at Licensor's expense, with all assistance, information and authority reasonably required for the defense and settlement of the Underlying Claim. Licensor's total liability under this Section 4.2 shall be limited to amounts received by Licensor under this Agreement.

(c) Notwithstanding any other provision in this Agreement to the contrary, the Parties agree that if any payment pursuant to Section 1 of this Agreement is subject to a Withholding Tax in any jurisdiction and if withholding from such payment is required or permitted by applicable law or administrative guidance, such Withholding Tax (including surcharges) shall be borne solely by the Party that is entitled to the consideration (including any amount credited) that is subject to the Withholding Tax, and such Party shall hold harmless and shall indemnify the respective other Party from any liabilities or losses related thereto.

4.3 Release.

(a) Effective upon receipt of the License Fee, Licensor and its Affiliates shall

automatically be deemed to, and Licensor, on behalf of itself and its Affiliates does hereby, forever waive and release all Claims, known or unknown, based in whole or in part on acts prior to the Effective Date of this Agreement that Licensor or its Affiliates may have against RPX, any RPX Affiliate, any RPX Licensee, any RPX Licensee Affiliates, or any other Entity (including but not limited to Covered Third Parties) granted a sublicense under the Patents in accordance with Section 1.2.

(b) Licensor, on behalf of itself and its Affiliates, understands and agrees that the releases set forth in Section 4.3(a) shall extend to any and all Claims described in Section 4.3(a) of every nature and kind whatsoever, whether such Claims are known or unknown, suspected or unsuspected, and any and all rights that may exist under Section 1542 of the California Civil Code (or any law of any jurisdiction, or principle of common law, which is similar, comparable or equivalent to California Civil Code Section 1542) ("Section 1542") within the scope of the release set forth in Section 4.3(a) are expressly waived. Licensor, on behalf of itself and its Affiliates, expressly acknowledges that it has read Section 1542, which provides as follows:

A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY.

Licensor, on behalf of itself and its Affiliates, understands and agrees that Section 1542, if applicable herein, gives it and its Affiliates the right not to release existing claims of which it and its Affiliates are not now aware of and do not suspect to exist, unless it voluntarily chooses to waive this right. Even though Licensor, on behalf of itself and its Affiliates, is aware of this right, Licensor, on behalf of itself and its Affiliates nevertheless hereby voluntarily waives the right described in Section 1542, and elects to assume all risks for Claims that now exist in its (and/or its Affiliates') favor, known or unknown, arising from the subject matter of the release set forth in Section 4.3(a), and expressly waives any rights under any other statutes or common law principles of similar effect. If, contrary to the specific intent of Licensor (or its Affiliates), any Claims released under Section 4.3(a) are deemed to exist or survive despite the releases given in Section 4.3(a) above, Licensor, on behalf of itself and its Affiliates, hereby forever, expressly and irrevocably waives entitlement to all such Claims, known and unknown, prior to the Effective Date, and it is expressly agreed that the provisions of Section 1542 do not apply.

Section 5. Miscellaneous

5.1 Binding Effect and Assignment. This Agreement shall not be binding upon the Parties until it has been signed herein below by or on behalf of each Party. This Agreement shall be binding on, and shall inure to the benefit of, the Parties hereto and their respective Affiliates, successors and assigns. No amendment or modification hereof shall be valid or binding upon the Parties unless made in writing and signed as aforesaid. Without limiting the foregoing, in no event

will either Party allege that any oral discussions, emails, texts or the like constitute an amendment to this Agreement or otherwise constitute a binding agreement between the Parties. The Patent License and any sublicenses granted and/or included therein pursuant to Section 1.2 are for the benefit of RPX, RPX Licensees, RPX Licensee Affiliates, and each of their respective Covered Third Parties, and RPX and RPX Licensees can legally enforce such licenses and sublicenses, as well as the terms of this Agreement, against Licensor and its Affiliates. The CTSL granted pursuant to Section 1.3 is for the benefit of RPX and Grantee, and RPX and Grantee can legally enforce the terms of this Agreement against Licensor and its Affiliates.

5.2 Notices. Notices and other communications relevant to this Agreement or to any of the Patents shall be sent by electronic mail, hand delivery, or by registered or certified mail to the following address, or to such other address as may be given by notice hereafter, and shall be effective upon sending, if sent by electronic mail, as proven by electronic date stamp, or upon receipt if sent by registered or certified mail, as proven by a post office delivery receipt:

For Licensor:

Greenthread, LLC
c/o Philip W. John
7424 Mason Dells Drive
Dallas, TX 75230-3244
Email: john@greenthreadllc.com

For RPX:

RPX Corporation
Four Embarcadero Center, Suite 4000
San Francisco, CA 94111
ATTN: Legal Department
Email: legal@rpxcorp.com

5.3 Severability. If any section of this Agreement is found by competent authority to be invalid, illegal, or unenforceable in any respect for any reason, the validity, legality, and enforceability of any such section in every other respect and the remainder of this Agreement shall continue in effect so long as the Agreement still expresses the intent of the Parties.

5.4 Governing Law. This Agreement, including its formation, shall be governed by and construed, and the legal relations between the Parties hereto shall be determined, in accordance with the law of the State of Delaware, United States of America, as such law applies to contracts signed and fully performed in such State, without regard to the principles of conflicts of law thereof.

5.5 Section Headings. The headings of sections are inserted for convenience of reference only and are not intended to be part of or to affect the meaning or interpretation of this Agreement.

5.6 Confidentiality. Neither Party hereto shall disclose the terms of this Agreement to any third party, without the prior written consent of the other Party. This obligation is subject to the following exceptions: (a) disclosure by the Parties and their Affiliates is permissible if required by government or court order, discovery request, or subpoena in pending Licensor Litigations, provided that: (i) the disclosing Party first gives the other Party prior written notice in order to enable that Party to seek a protective order or motion to quash (or other equivalent protection), such permissible disclosure limited to the terms legally required to be disclosed, and (ii) any such disclosure is subject to protective order, with such permissible disclosure protected under an “Outside Attorneys Eyes Only” or higher confidentiality designation; or if before the Patent Trial and Appeal Board (the “Board”), under a “Business Confidential” designation viewable only by the Board, and any disclosure of financial terms that may be required by the International Trade Commission (the “ITC”) will be made by Licensor only, under a confidentiality designation that is viewable only by the ITC, its staff; (b) disclosure by the Parties and their Affiliates is permissible if otherwise required by any applicable securities exchange rules or regulations, such permissible disclosure limited to the terms legally required to be disclosed; (c) the Parties and their Affiliates may disclose this Agreement or its contents to the extent reasonably necessary, on a confidential basis, to each of their respective accountants, attorneys, insurance partners, and financial advisors; (d) RPX and its Affiliates may disclose the non-financial terms of this Agreement to Grantee, any RPX Licensees and any other potential sublicensees of the Patents, including Covered Third Parties; (e) either Party may disclose any information that was made publicly available without a breach of this Agreement; and (f) RPX may issue a press release (without disclosing any financial terms) following the execution of this Agreement to announce the consummation of this transaction. If Licensor is notified that any federal government agency or third party is requesting to have the terms of this Agreement made available, Licensor immediately shall notify RPX in writing.

5.7 Entire Agreement. This Agreement, including the exhibits attached hereto, embodies the entire understanding of and agreement between the Parties with respect to the Patents and merges and supersedes all prior agreements, understandings, negotiations, and discussions between the Parties. Neither Party shall be bound by any condition, definition, warranty, understanding or representation with respect to the subject matter hereof other than as expressly provided herein. Notwithstanding anything to the contrary, nothing in this Agreement will limit or narrow any rights granted under that Agreement entered into by and between RPX and Licensor dated July 8, 2020. Notwithstanding the foregoing, but subject to the confidentiality terms set forth in Section 5.6, the nondisclosure agreement previously entered into by and between the Parties remains in full force and effect. For the avoidance of doubt, nothing in this Agreement is intended to (a) revoke, narrow, terminate, or require a refund of any payment received under any prior license, settlement, release or other grant of rights between Licensor and any RPX Licensee, Grantee and/or their respective Affiliates, or the respective Covered Third Parties or (b) revive or preserve in the name of Licensor, any of its Affiliates or any successors in interest any claims otherwise released and dismissed by Licensor or its Affiliates under any Patents.

5.8 Counterparts. This Agreement may be executed by the Parties in one or more counterparts, each of which shall be an original and all of which shall together constitute one and the same instrument.

5.9 Relationship of the Parties. Nothing contained herein, or done in pursuance of this Agreement, will constitute the Parties entering into a joint venture or partnership or will constitute either Party hereto being the agent for the other Party for any purpose or in any sense whatsoever.

5.10 Licenses of Intellectual Property. All rights, licenses and releases granted by Licensor, on behalf of itself and its Affiliates, directly or indirectly to RPX, RPX Affiliates, RPX Licensees, Grantee, and Covered Third Parties (including each such Entity's Affiliates) are, and shall otherwise be deemed to be, for the purpose of Section 365(n) of the United States Bankruptcy Code, as amended (the "Bankruptcy Code"), licenses of rights to "intellectual property" as defined under Section 101 of the Bankruptcy Code. The Parties hereto agree that RPX, RPX Affiliates, RPX Licensees, Grantee, and Covered Third Parties (including each such Entity's Affiliates), as licensees or sublicensees or recipients of rights granted in this Agreement, shall retain and may fully exercise all their rights and elections under the Bankruptcy Code. The Parties hereto further agree that, in the event that any proceeding shall be instituted by or against Licensor seeking to adjudicate it as bankrupt or insolvent, or seeking liquidation, winding up, reorganization, arrangement, adjustment, protection, relief or composition of it or its debts under any law relating to bankruptcy, insolvency, or reorganization or relief of debtors, or seeking an entry of an order for relief or the appointment of a receiver, trustee or other similar official for it or any substantial part of its property or it shall take any action to authorize any of the foregoing actions, the opposite Parties shall have the right to retain and enforce their rights under this Agreement, provided that they remain in full compliance with the terms and conditions of this Agreement.

5.11 Authorship. Neither Party shall be considered the author of this Agreement for the purpose of interpreting any provision herein.

5.12 Acknowledgement. Licensor acknowledges that nothing in this Agreement shall require or shall be construed to require RPX or any RPX Affiliate to sue or threaten to sue (or instruct, encourage, or aid a third party to sue or threaten to sue) any Entity.

5.13 Termination and Survival. The term of this Agreement shall commence upon the Effective Date and shall continue until the expiration of the last to expire patent that is or could be a Patent. Those provisions that by their nature are intended to survive termination or expiration of this Agreement shall so survive. For the avoidance of doubt, the Patent License granted by Licensor to RPX hereunder, the CTSL granted by Licensor hereunder, RPX's right to grant sublicenses and CTSLs in accordance with Section 1, all sublicenses and CTSLs granted by RPX in accordance with Section 1, and all releases covenants, representations and warranties given by Licensor shall survive termination or expiration of this Agreement.

5.14 No Domestic Industry. Licensor agrees on behalf of itself, its Affiliates, and their successors and assigns not to claim that the rights conveyed in this Agreement, or the alleged practice of any Patents by any Entity covered under this Agreement, constitute evidence of a domestic industry pursuant to Section 337(a) of the Tariff Act of 1930 or any similar foreign or domestic statute, and hereby irrevocably waives any such argument.

[The remainder of this page is blank; signature page follows.]

IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed as of the Effective Date. Each individual signing below represents and warrants that he or she has authority to sign for and enter into this Agreement on behalf of his or her respective Party.

Agreed to:

Agreed to:

GREENTHREAD, LLC**RPX CORPORATION**By: Philip W JohnBy: Daniel P. McCurdyName: Philip W JohnName: Daniel P. McCurdyTitle: PRESIDENTTitle: Chief Executive OfficerDate: APRIL 7, 2023Date: April 7, 2023

EXHIBIT A

INITIAL LICENSEES

Intel Corporation



EXHIBIT B**PATENTS**

Fam ily	Patent No.	Publication No.	Application No.	Title	File Date	Publication Date
1		US200600494 64	US10/934915	Semiconductor devices with graded dopant regions	9/3/20 04	3/9/2006
1	US8421 195		US11/622496	Semiconductor devices with graded dopant regions	1/12/2 007	4/16/2013
1	US8106 481		US12/549283	Semiconductor devices with graded dopant regions	8/27/2 009	1/31/2012
1		US201302214 88	US13/854319	Semiconductor devices with graded dopant regions	4/1/20 13	8/29/2013
1	US9190 502		US14/515584	Semiconductor devices with graded dopant regions	10/16/ 2014	11/17/2015
1	US9647 070		US14/931636	Semiconductor devices with graded dopant regions	11/3/2 015	5/9/2017
1	US1051 0842		US15/590282	Semiconductor devices with graded dopant regions	5/9/20 17	12/17/2019
1	US1073 4481		US16/717950	Semiconductor devices with graded dopant regions	12/17/ 2019	8/4/2020
1	US1112 1222		US16/947294	Semiconductor devices with graded dopant regions	7/27/2 020	9/14/2021
1	US1131 6014		US17/371839	Semiconductor devices with graded dopant regions	7/9/20 21	4/26/2022
1		US202202467 25	US17/728588	Semiconductor devices with graded dopant regions	4/25/2 022	8/4/2022

EXHIBIT C**RELEASE TERMS**

This RELEASE AGREEMENT (“**Release Agreement**”) is entered into by and between [____], a [____] company with a principal place of business at [____] (including its Affiliates, as defined below) (“**Licensor**”), and [____],¹ a [____] corporation with a principal place of business at [____] (including its Affiliates), “[**RELEASED ENTITY**”], on the last date when this Release Agreement has been executed by both Licensor and [RELEASED ENTITY] (the “**Effective Date**”).

“**Affiliate(s)**” of an Entity shall mean any and all Entities, now or in the future and for so long as the Control exists, that are Controlled, directly or indirectly, by the Entity.

“**Claims**” shall mean any and all claims, counterclaims, third-party claims, contribution claims, indemnity claims, demands, actions, liabilities, damages, losses, causes of action, and all other claims of every kind and nature in law or equity, whether arising under state, federal, international or other law, which arise from or relate to in any way the Patents or which are (currently or in the future) or were asserted in, could have been asserted in, or which arise from the same transactions or occurrences as those claims that are (currently or in the future) or were asserted in the Licensor Litigation, whether such claims are absolute or contingent, in tort, contract or otherwise, direct or indirect, past, present or future, known or unknown.

“**Combined Licensed Product and Service**” shall mean any past, present or future combination or use, whether by [RELEASED ENTITY], [RELEASED ENTITY]’s Affiliate, or a third party, of a Licensed Product and Service with any other product, service, technology, or material, only if such Licensed Product and Service or a portion thereof provided by or on behalf of [RELEASED ENTITY] or [RELEASED ENTITY] Affiliate satisfies, in whole or in part, an element or a step of a claim in any Patent. For clarity, a Combined Licensed Product and Service will not include any product, service, technology or material of any Entity that is not [RELEASED ENTITY] or [RELEASED ENTITY] Affiliate that independently satisfies all of the elements of a claim in any Patent, provided that Licensor has not and does not allege that any Licensed Product and Service of [RELEASED ENTITY] or any [RELEASED ENTITY] Affiliate satisfies, in whole or in part, an element or step of a claim in any Patent.

“**Control**” shall mean the legal, beneficial, and/or equitable ownership (directly or indirectly) of more than fifty percent (50%) of (i) the voting power representing the right to vote for directors or other managing authority, (ii) equity ownership interest in an Entity, or (iii) other ownership interest in an Entity.

“**Effective Date**” shall have the meaning ascribed to it in the preamble.

¹ Note: The Release Agreement shall be executed by the parent company of the applicable defendant in the Licensor Litigation(s), and the Release Agreement shall apply to such parent company and its Affiliates

“Entity” shall mean a corporation, association, partnership, business trust, joint venture, limited liability company, proprietorship, unincorporated association, individual or other entity that can exercise independent legal standing.

“Licensed Product and Service” shall mean any past, present or future product, service, software, firmware, macros, technology, integrated circuits, systems, IP blocks, cores, cells, designs, specifications, or material (including any components, devices, data, media, or any other portions thereof) at any time, made, have made, used, purchased, provided, hosted, sold, leased, licensed, distributed, transmitted, exported, imported or offered for sale, lease, or import or otherwise exploited or disposed of by or on behalf of an [RELEASED ENTITY] or any [RELEASED ENTITY] Affiliates (along with any designs, methods, or processes for the manufacture or operation thereof), alone or in combination (including as a Combined Licensed Product and Service) with other products, software, technology, materials and services, the manufacture, use, purchase, provision, hosting, sale, lease, license, distribution, transmittal, export, import (or offer for sale, lease or import) of which would result in infringement (direct, indirect, or otherwise) of one or more Patents, irrespective of whether the product, service, software, firmware, macros, technology, integrated circuits, systems, IP blocks, cores, cells, designs, specifications, or material (including any components, devices, data, media, or any other portions thereof) were or had been made, used, purchased, provided, hosted, sold, leased, licensed, distributed, transmitted, exported, imported or offered for sale, lease, or import in the United States.

“Licensor” shall have the meaning ascribed to it in the preamble.

“Licensor Litigation” shall mean [INSERT CASE NAME, NUMBER, AND JURISDICTION].

“Patents” shall mean: (i) the patents and patent applications identified on Schedule 1, together with any and all patents and patent applications that are owned, controlled, or licensable as of the Effective Date or later by Licensor and/or its Affiliates, and any and all foreign counterparts of any of the foregoing; (ii) any and all patents that have issued or may issue from any of the patents or patent applications described in (i) of this definition; (iii) any and all patents and patent applications that, in whole or in part, claim priority to (directly or indirectly), or the benefit of the filing date of, any of the patents or patent applications described in (i) or (ii) of this definition, including any and all child, continuation, continuation-in-part, continuing prosecution, divisional, provisional, non-provisional, reissue, reexamination, substitution, post-issuance trial certificate, extension and counterpart patents and patent applications of any of the patents or patents applications described in (i) or (ii) of this definition; (iv) any and all patents and patent applications from which any of the patents or patent applications described in (i), (ii) or (iii) of this definition, in whole or in part, claim the benefit of priority (directly or indirectly) or otherwise claim the benefit of the filing date, including any and all parent patents or patent applications of any of the patents or patent applications described in (i), (ii) or (iii) of this definition; and (v) any and all extensions or renewals of any of the patent or patent applications described in this definition. Any one of the foregoing is a **“Patent”**. Licensor is not granting, and does not have any authority to grant, any rights, express or implied, to U.S. Patent Nos. 8,891,298; 9,196,385; 9,997,240; 10,950,300, or any patent claiming priority directly or indirectly from or through application in common with such patents (i.e. any parent or child of such patents); or any other patents or patent applications owned or Controlled by Vervain LLC (“Vervain Patents”), so long as the Vervain

Patents are not owned, controlled, or licensable by Licensor and/or its Affiliates.

“Release Agreement” shall have the meaning ascribed to it in the preamble.

“[RELEASED ENTITY]” shall have the meaning ascribed to it in the preamble.

Mutual Release.

Except with respect to the obligations created by or arising out of this Release Agreement, Licensor does hereby for itself and its respective legal successors, Affiliates, heirs and assigns, irrevocably release and absolutely discharge [RELEASED ENTITY], each [RELEASED ENTITY] Affiliate, and each of [RELEASED ENTITY]’s and each [RELEASED ENTITY] Affiliate’s respective direct and indirect customers, suppliers, have-made vendors, dealers, manufacturers, original equipment manufacturers (OEMs), original design manufacturers (ODMs), system integrators, other contractors, licensees, developers, users (including end users), distributors, dealers, employees, representatives, agents, officers, directors, parents, subsidiaries, past and present (each, a “Covered Third Party”), of and from any and all Claims based in whole or in part on acts of [RELEASED ENTITY] or any [RELEASED ENTITY] Affiliate prior to the Effective Date of this Release Agreement. To the extent that, after the Effective Date, Licensor or its Affiliates owns any right, title or interest in, or has exclusive license rights (or the right to grant rights) under, any patents or patent applications that are not expressly listed on Schedule 1, then (i) such patents and patent applications are intended to be, and shall be treated as if they are, included on Schedule 1; and (ii) the release granted in the foregoing sentence with respect to such patents and patent applications shall become effective immediately as of the first date that each such patent or patent application becomes owned, controlled, or licensable by Licensor or its Affiliates. The release granted in this paragraph further extends to Covered Third Parties, solely to the extent of their use, purchase, sale, importation, offer for sale or distribution of Licensed Products or Services and/or Combined Licensed Product and Services.

Except with respect to the obligations created by or arising out of this Release Agreement, [RELEASED ENTITY], each [RELEASED ENTITY] Affiliate², and each of their respective legal successors, heirs and assigns, release and absolutely discharge Licensor, and each of Licensor’s employees, representatives, agents, officers, directors, parents, subsidiaries, past and present, solely of and from any and all Claims, demands, damages, debts, liabilities, accounts, reckonings, obligations, costs, expenses, liens, attorneys’ fees, actions and causes of action of every kind and nature whatever, arising out of the institution, filing, prosecution and resolution of the Licensor Litigation. Nothing in this Release Agreement, however, shall extinguish, impair or otherwise affect any defense, Claim, or position of [RELEASED ENTITY] that the Patents are not infringed, invalid and/or not enforceable. Accordingly, with respect to any defenses, Claims, and/or challenges relating to the Patents, [RELEASED ENTITY] shall be in the same position as though the Licensor Litigation had never been brought.

The parties acknowledge and agree that this Release Agreement fully and finally releases and forever resolves the Licensor Litigation, including those Claims identified above involving the Patents and the Licensed Products and Services and/or Combined Licensed Product and Services

² [RELEASED ENTITY] may elect to add the phrase “wholly owned” to modify its Affiliates.

that are unknown, unanticipated or unsuspected or that may hereafter arise as a result of the discovery of new and/or additional facts. The parties acknowledge and understand the significance and potential consequence of the release of unknown claims. The parties intend that the claims released under this Release Agreement be construed as broadly as possible and agree to waive and relinquish all rights and benefits each may have under Section 1542 of the Civil Code of the State of California, or any similar statute or law of any other jurisdiction. Section 1542 reads as follows: “A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY.”

[To the extent that [RELEASED PARTY] or any of its Affiliates has initiated Claims (or any Inter partes reviews or other invalidity or nullity proceedings before the PTO or any other US or foreign court or administrative body) relating to any Patent (“Challenge”), the Parties will mutually cooperate to request the termination of proceedings related to such Challenge. Such request for the termination of proceedings related to any such Challenge will be made immediately after a fully-executed dismissal with prejudice with respect to any Licensor Litigations pending against [RELEASED ENTITY] and/or its Affiliates is entered by the applicable court, but only to the extent that Licensor and [RELEASED ENTITY] possess the authority to request the termination of such petitions. If such petition has been co-filed with any third-party, then after a fully-executed dismissal with prejudice with respect to any Licensor Litigations pending against [RELEASED PARTY] and/or its Affiliates is entered by the applicable court, [RELEASED PARTY] and/or its Affiliates will immediately discontinue any substantive involvement in such Challenge, following which [RELEASED PARTY]’s and/or its Affiliates’ obligations under this section will be deemed satisfied.]³

No Admission of Liability. The Parties agree that the settlement of the Licensor Litigation is intended solely as a compromise of the disputed claims, and without any acknowledgment of liability, fault, damages, or any other merits of the Licensor Litigation.

Notice. Any notice or communication required or permitted to be given by either Party hereunder shall be in written form and shall be considered to be sufficiently given if mailed by registered or certified mail or transmitted by overnight courier, addressed to the Parties hereto as follows:

To Licensor:

To [RELEASED ENTITY]:

Or to such changed address as the addressee shall have specified by written notice in accordance with this provision.

Governing Law. The Parties hereto agree that this Release Agreement shall be considered to have been made in, and construed and interpreted in accordance with the substantive laws of the State

³ This bracketed section to be included only if [RELEASED ENTITY] or any [RELEASED ENTITY] Affiliate has initiated an IPR or other invalidity or nullity proceeding relating to any Patent.

of Delaware of the United States of America.

Disputes. The Parties hereto shall use their best efforts to resolve by mutual agreement any disputes, controversies or differences that may arise from, under, out of or in connection with the Release Agreement. If any such disputes, controversies or differences cannot be settled between the Parties hereto within thirty (30) days, they shall be finally brought in federal district court in [RELEASED ENTITY]'s choice of venue, and the Parties hereby submit to the jurisdiction of, and waive any venue objections against such venue. Should such venue lack jurisdiction, the Parties hereby submit to the exclusive jurisdiction of the state courts of the State chosen by [RELEASED ENTITY].

Representations and Warranties. Licensor, on behalf of itself and its Affiliates, represents and warrants that it is a [] company in good standing under the laws of the state of []; that it has the authority to enter into this Agreement; and that this Agreement is valid, binding and enforceable in accordance with its terms. Licensor further represents and warrants that it has sufficient right, title, and interest to grant the release conveyed in this Release Agreement. [RELEASED ENTITY] represents and warrants that it is a [corporation] in good standing under the laws of the state of []. [RELEASED ENTITY] further represents and warrants that it has the authority to enter into this Release Agreement; and that this Release Agreement is valid, binding and enforceable in accordance with its terms.

Confidentiality. Neither Party will disclose the terms or existence of this Agreement, except:

1. As required by any law, rule, regulation, order, discovery request, subpoena or other governmental requirement (including public reporting requirements); provided that such disclosure is made pursuant to a protective order or agreement providing confidentiality protections at least as stringent as those provided in this paragraph, to the extent possible;
2. To such Party's accountants, attorneys, financial advisors and other professionals engaged by such Party, as reasonably required for their performance of services for such Party; provided that such disclosure will be governed by the confidentiality provisions set forth herein;
3. As reasonably required for due diligence in connection with any proposed assignment of this Agreement or any transaction involving [RELEASED ENTITY] or a [RELEASED ENTITY] Affiliate; provided that such disclosure will be governed by the confidentiality provisions set forth herein;
4. A Party may disclose any information that becomes part of the public domain without a breach of this Section by the disclosing Party;
5. With the prior written consent of the other Party;
6. Both Parties may disclose that "the dispute between the parties has been resolved;"
7. [RELEASED ENTITY] may disclose in the course of any legal proceeding to support any claim or defense; provided that such disclosure is made pursuant to a protective order or

agreement providing confidentiality protections at least as stringent as those provided in this paragraph, to the extent possible;

8. [RELEASED ENTITY] may disclose to any Covered Third Party the existence and terms of this Release Agreement; provided that any disclosure of the terms of this Release Agreement will be governed by the confidentiality provisions set forth herein.

No Right to Terminate. Neither Party may terminate this Release Agreement without the express, written consent of the other Party.

No Domestic Industry. Licensor agrees on behalf of itself, its Affiliates, and their successors and assigns not to claim that the rights conveyed to [RELEASED ENTITY] in this Release Agreement or [RELEASED ENTITY]'s alleged practice of any Patents are evidence of a domestic industry pursuant to Section 337(a) of the Tariff Act of 1930 or any similar foreign or domestic statute, and hereby irrevocably waives any such argument.

Entire Agreement. This Release Agreement constitutes the entire agreement between the Parties concerning the subject matter hereof and supersedes all written and oral prior agreements and understandings with respect thereto. No variation or modification of the terms of this Release Agreement, nor any waiver of any of the terms or provisions hereof, shall be valid unless in writing and signed by an authorized representative of each Party.

Counterparts. This Release Agreement may be executed in two counterparts in the English language and each such counterpart shall be deemed an original thereof. Facsimile signatures or signatures delivered by e-mail in .pdf or similar format will be deemed original signatures for purposes of this Release Agreement.

[The remainder of this page is blank; signature page follows.]

IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed as of the Effective Date. Each individual signing below represents and warrants that he or she has authority to sign for and enter into this Agreement on behalf of his or her respective Party.

Agreed to:

Agreed to:

[LICENSOR]**[RELEASED ENTITY]**

By: _____

By: _____

Name: _____

Name: _____

Title: _____

Title: _____

Date: _____

Date: _____

SCHEDULE 1**PATENTS***[See Exhibit B]*

EXHIBIT D
FORM OF DISMISSAL

IN THE UNITED STATES DISTRICT COURT
FOR THE [] DISTRICT OF []

[] Plaintiff, v. [], ET AL., Defendants.	CIVIL ACTION NO. []-CV-[]
---	------------------------------------

JOINT MOTION TO DISMISS

WHEREAS, Plaintiff [] (“Plaintiff”) and Defendant [] (“[]”) have resolved Plaintiff’s claims for relief against [] and []’s counterclaims for relief against Plaintiff asserted in this case.

NOW, THEREFORE, Plaintiff and [], through their attorneys of record, request this Court to dismiss Plaintiff’s claims for relief against [] with prejudice and []’s claims, defenses or counterclaims for relief against Plaintiff, to the extent they exist, with prejudice, and with all attorneys’ fees, costs of court and expenses borne by the party incurring same.

_____, 20____

/s/_____

Respectfully submitted,

/s/_____

ATTORNEY FOR PLAINTIFF

[]

ATTORNEY FOR DEFENDANT

[]

CONFIDENTIAL

IN THE UNITED STATES DISTRICT COURT
FOR THE [] DISTRICT OF []

[]

Plaintiff,

v.

[], ET AL.,

Defendants.

CIVIL ACTION NO. []-CV-[]

ORDER OF DISMISSAL WITH PREJUDICE

On this day, Plaintiff [] (“Plaintiff”) and Defendant and Counterclaim-Plaintiff [] (“[]”) announced to the Court that they have resolved Plaintiff’s claims for relief against [] asserted in this case and []’s claims, defenses and/or counterclaims for relief against Plaintiff asserted in this case. Plaintiff and [] have therefore requested that the Court dismiss Plaintiff’s claims for relief against [] with prejudice and []’s claims, defenses and/or counterclaims for relief against Plaintiff, to the extent they exist, with prejudice, and with all attorneys’ fees, costs and expenses taxed against the party incurring same. The Court, having considered this request, is of the opinion that their request for dismissal should be granted.

IT IS THEREFORE ORDERED that Plaintiff’s claims for relief against [] are dismissed with prejudice and []’s claims, defenses and/or counterclaims for relief against Plaintiff are dismissed without prejudice. IT IS FURTHER ORDERED that all attorneys’ fees, costs of court and expenses shall be borne by each party incurring the same.

CONFIDENTIAL

EXHIBIT E

LICENSEE NULLITY PROCEEDINGS AND LICENSOR LITIGATIONS

Greenthread, LLC v. Intel Corporation, 22-cv-02001-JR (D. Or.)

Intel Corp. v. Greenthread LLC, IPR2023-00260

Intel Corp. v. Greenthread LLC, IPR2023-00308

Intel Corp. v. Greenthread LLC, IPR2023-00386

Intel Corp. v. Greenthread LLC, IPR2023-00420

Intel Corp. v. Greenthread LLC, IPR2023-00541

Intel Corp. v. Greenthread LLC, IPR2023-00548

Intel Corp. v. Greenthread LLC, IPR2023-00552

CONFIDENTIAL

EXHIBIT F**CTSL AGREEMENT**

This CTSL AGREEMENT (“**Agreement**”) is entered into by and between [____], a [____] company with a principal place of business at [____] (including its Affiliates, as defined below) (“**Grantor**”), and [____],⁴ a [____] corporation with a principal place of business at [____] (including its Affiliates), “[**RELEASED ENTITY**]”, on the last date when this Agreement has been executed by both Grantor and [RELEASED ENTITY] (the “**Effective Date**”).

“**Affiliate(s)**” of an Entity shall mean any and all Entities, now or in the future and for so long as the Control exists, that are Controlled, directly or indirectly, by the Entity.

“**Control**” shall mean the legal, beneficial, and/or equitable ownership of more than fifty percent (50%) of (i) the voting power representing the right to vote for directors or other managing authority, (ii) equity ownership interest in an Entity, or (iii) other ownership interest in an Entity.

“**CTSL**” (Covenant to Sue Last) shall have the meaning ascribed to it below.

“**Effective Date**” shall have the meaning ascribed to it in the preamble.

“**Entity**” shall mean a corporation, association, partnership, business trust, joint venture, limited liability company, proprietorship, unincorporated association, individual or other entity that can exercise independent legal standing.

“[**GRANTEE**]” shall have the meaning ascribed to it in the preamble.

“**Grantor**” shall have the meaning ascribed to it in the preamble.

“**Grantor Litigation**” shall mean [INSERT CASE NAME, NUMBER, AND JURISDICTION].

“**Patents**” shall mean: (i) the patents and patent applications identified on Schedule 1, together with any and all patents and patent applications that are owned, controlled, or licensable as of the Effective Date or later by Grantor and/or its Affiliates, and any and all foreign counterparts of any of the foregoing; (ii) any and all patents that have issued or may issue from any of the patents or patent applications described in (i) of this definition; (iii) any and all patents and patent applications that, in whole or in part, claim priority to (directly or indirectly), or the benefit of the filing date of, any of the patents or patent applications described in (i) or (ii) of this definition, including any and all child, continuation, continuation-in-part, continuing prosecution, divisional, provisional, non-provisional, reissue, reexamination, substitution, post-issuance trial certificate, extension and counterpart patents and patent applications of any of the patents or patents

⁴ Note: This Agreement may be executed by the parent company of the applicable defendant in the litigation(s), and the Agreement shall apply to such parent company and its Affiliates.

CONFIDENTIAL

applications described in (i) or (ii) of this definition; (iv) any and all patents and patent applications from which any of the patents or patent applications described in (i), (ii) or (iii) of this definition, in whole or in part, claim the benefit of priority (directly or indirectly) or otherwise claim the benefit of the filing date, including any and all parent patents or patent applications of any of the patents or patent applications described in (i), (ii) or (iii) of this definition; and (v) any and all extensions or renewals of any of the patent or patent applications described in this definition. Any one of the foregoing is a “Patent”. Grantor is not granting, and does not have any authority to grant, any rights, express or implied, to U.S. Patent Nos. 8,891,298; 9,196,385; 9,997,240; 10,950,300, or any patent claiming priority directly or indirectly from or through application in common with such patents (i.e. any parent or child of such patents); or any other patents or patent applications owned or Controlled by Vervain LLC (“Vervain Patents”), so long as the Vervain Patents are not owned, controlled, or licensable by Grantor and/or its Affiliates.

CTSL.

Effective upon the Effective Date, Grantor, on behalf of itself, its Affiliates, and each of their respective successors and assigns, shall automatically be deemed to grant, and does hereby grant, to [GRANTEE], [GRANTEE]’s Affiliates, and any business unit or division that [GRANTEE] or its Affiliates may divest, the CTSL. The CTSL shall mean: Grantor agrees, on behalf of itself, its Affiliates, and each of their respective successors and assigns, that it can sue [GRANTEE], [GRANTEE]’s Affiliates, and any business unit or division that [GRANTEE] or its Affiliates may divest (or any downstream customers of [GRANTEE], [GRANTEE]’s Affiliates, and any business unit or division that [GRANTEE] or its Affiliates may divest, based on any products and/or services of [GRANTEE], [GRANTEE]’s Affiliates, and any business unit or division that [GRANTEE] or its Affiliates may divest) for direct or indirect infringement (including, without limitation, inducement, or contributory infringement) under any of the Patents, only after Grantor has first fully pursued and exhausted any and all claims for infringement of the Patents (including any and all appeals and all available efforts to collect any judgment or settlement amount) against any and all other Entities. Licensor represents and warrants that, as of the Effective Date, at least one such other Entity exists against whom it has a claim for infringement of each Patent. Notwithstanding anything to the contrary, the existence and/or grant of the CTSL will not be used in connection with establishing or alleging against Grantee any claim of willful patent infringement.

No Admission of Liability. The Parties agree that this Agreement is intended solely as a compromise of the disputed claims, and without any acknowledgment of liability, fault, damages, or any other merits of the Grantor Litigation.

IPRs. [GRANTEE] (or its Affiliate, as applicable) and Grantor will mutually cooperate to request termination of any and all any *inter partes reviews* (“IPR”) or other proceedings before the PTO—or any other invalidity or nullity proceeding anywhere in the world—but only to the extent that Grantor and [GRANTEE] (or its Affiliates, as applicable) possess the power to terminate such petitions.⁵ Such request for the termination of proceedings related to any such IPR will be made

⁵ [GRANTEE] may elect to add the phrase: “Grantor stipulates that it will not reference, submit or otherwise use (i)

CONFIDENTIAL

immediately after a fully-executed dismissal without prejudice with respect to any Grantor Litigation pending against [GRANTEE] and/or its Affiliates is filed with the applicable court. In the event the proceeding is not terminated, [GRANTEE] and its Affiliates will withdraw from such proceedings. All fees and costs will be borne by party that incurred them, both for Grantor Litigations and IPRs.

Rights of Intellectual Property. All rights granted by Grantor, on behalf of itself and its Affiliates, directly or indirectly to [GRANTEE] and [GRANTEE]'s Affiliates are, and shall otherwise be deemed to be, for the purpose of Section 365(n) of the United States Bankruptcy Code, as amended (the "Bankruptcy Code"), rights to "intellectual property" as defined under Section 101 of the Bankruptcy Code. The Parties hereto agree that [GRANTEE] and its Affiliates, as recipients of rights granted in this Agreement, shall retain and may fully exercise all their rights and elections under the Bankruptcy Code. The Parties hereto further agree that, in the event that any proceeding shall be instituted by or against Grantor seeking to adjudicate it as bankrupt or insolvent, or seeking liquidation, winding up, reorganization, arrangement, adjustment, protection, relief or composition of it or its debts under any law relating to bankruptcy, insolvency, or reorganization or relief of debtors, or seeking an entry of an order for relief or the appointment of a receiver, trustee or other similar official for it or any substantial part of its property or it shall take any action to authorize any of the foregoing actions, the opposite Parties shall have the right to retain and enforce their rights under this Agreement, provided that they remain in full compliance with the terms and conditions of this Agreement.

Notice. Any notice or communication required or permitted to be given by either Party hereunder shall be in written form and shall be considered to be sufficiently given if mailed by registered or certified mail or transmitted by overnight courier, addressed to the Parties hereto as follows:

To Grantor:

To [GRANTEE]:

Or to such changed address as the addressee shall have specified by written notice in accordance with this provision.

Governing Law. The Parties hereto agree that this Agreement shall be considered to have been made in, and construed and interpreted in accordance with the substantive laws of the State of Delaware of the United States of America.

Disputes. The Parties hereto shall use their best efforts to resolve by mutual agreement any disputes, controversies or differences that may arise from, under, out of or in connection with the Agreement. If any such disputes, controversies or differences cannot be settled between the Parties hereto within thirty (30) days, they shall be finally brought in federal district court in

the Grantor Litigation, (ii) the filing of IPRs prior to the Effective Date, or (iii) these requests to terminate in connection with any future proceeding before the Board brought by [GRANTEE], including without limitation as part of a petition seeking denial under 35 U.S.C. §§ 314, 315."

CONFIDENTIAL

[GRANTEE]'s choice of venue, and the Parties hereby submit to the jurisdiction of, and waive any venue objections against such venue. Should such venue lack jurisdiction, the Parties hereby submit to the exclusive jurisdiction of the state courts of the State chosen by [GRANTEE].⁶

Representations and Warranties. Grantor represents and warrants that it is a [] company in good standing under the laws of the state of []; that it has the authority to enter into this Agreement; and that this Agreement is valid, binding and enforceable in accordance with its terms. Grantor further represents and warrants that it has sufficient right, title, and interest to grant the release conveyed in this Agreement. [GRANTEE] represents and warrants that it is a [corporation] in good standing under the laws of the state of []. [GRANTEE] further represents and warrants that it has the authority to enter into this Agreement; and that this Agreement is valid, binding and enforceable in accordance with its terms.

Confidentiality. Neither Party will disclose the terms or existence of this Agreement, except:

1. As required by any law, rule, regulation, order, discovery request, subpoena or other governmental requirement (including public reporting requirements); provided that such disclosure is made pursuant to a protective order or agreement providing confidentiality protections at least as stringent as those provided in this paragraph, to the extent possible. The Parties acknowledge and agree that any disclosure that may be required by the Patent Trial and Appeal Board (the "Board") will be made by Grantor only, under a "Business Confidential" designation that is viewable only by the Board and the filing party, and any disclosure of financial terms that may be required by the International Trade Commission (the "ITC") will be made by Grantor only, under a confidentiality designation that is viewable only by the ITC, its staff, and the filing party. If Grantor is notified by the Board that any federal government agency or any third party is requesting to have the terms of this Agreement made available, Grantor immediately shall notify [GRANTEE] in writing;
2. To such Party's accountants, attorneys, financial advisors and other professionals engaged by such Party, as reasonably required for their performance of services for such Party; provided that such disclosure will be governed by the confidentiality provisions set forth herein;
3. As reasonably required for due diligence in connection with any proposed assignment of this Agreement or any transaction involving [GRANTEE] or a [GRANTEE] Affiliate; provided that such disclosure will be governed by the confidentiality provisions set forth herein;

⁶ [GRANTEE] may elect to include the following: Notwithstanding anything to the contrary, if Grantor files suit against Grantee, Grantee's Affiliates, or any business unit or division that [GRANTEE] or its Affiliates may divest (or any or any downstream customers of [GRANTEE], [GRANTEE]'s Affiliates, and any business unit or division that [GRANTEE] or its Affiliates may divest, based on any products and/or services of [GRANTEE], [GRANTEE]'s Affiliates, and any business unit or division that [GRANTEE] or its Affiliates may divest), then the venue provisions herein shall not apply to, and shall not restrict or limit, any action, suit or proceeding brought before the United States Patent and Trademark Office or any other similar governmental body (e.g., the European Patent Office, Japanese Patent Office) regarding the validity, enforceability, grant or allowance of any Patent.

CONFIDENTIAL

4. A Party may disclose any information that becomes part of the public domain without a breach of this Section by the disclosing Party;
5. With the prior written consent of the other Party;
6. [GRANTEE] may disclose in the course of any legal proceeding to support any claim or defense; provided that such disclosure is made pursuant to a protective order or agreement providing confidentiality protections at least as stringent as those provided in this paragraph, to the extent possible;
7. [GRANTEE] may disclose to any [GRANTEE] Affiliate only the fact that Grantor has granted the CTSL under the Patents; provided that such disclosure will be governed by the confidentiality provisions set forth herein. The [GRANTEE] Affiliate(s) shall have the same confidentiality obligations as the Parties herein and specifically set forth in this section.

No Right to Terminate. Neither Party may terminate this Agreement without the express, written consent of the other Party.

No Domestic Industry. Grantor agrees on behalf of itself, its Affiliates, and their successors and assigns not to claim that the rights conveyed to [GRANTEE] in this Agreement or [GRANTEE]'s alleged practice of any Patents are evidence of a domestic industry pursuant to Section 337(a) of the Tariff Act of 1930 or any similar foreign or domestic statute, and hereby irrevocably waives any such argument.

Entire Agreement. This Agreement constitutes the entire agreement between the Parties concerning the subject matter hereof and supersedes all written and oral prior agreements and understandings with respect thereto. No variation or modification of the terms of this Agreement, nor any waiver of any of the terms or provisions hereof, shall be valid unless in writing and signed by an authorized representative of each Party.

Counterparts. This Agreement may be executed in two counterparts in the English language and each such counterpart shall be deemed an original thereof. Facsimile signatures or signatures delivered by e-mail in .pdf or similar format will be deemed original signatures for purposes of this Agreement.

[The remainder of this page is blank; signature page follows.]

IN WITNESS WHEREOF, the Parties hereto have caused this Agreement to be executed as of the Effective Date. Each individual signing below represents and warrants that he or she has authority to sign for and enter into this Agreement on behalf of his or her respective Party.

CONFIDENTIAL

Agreed to:

[GRANTOR]

By: _____

Name: _____

Title: _____

Date: _____

Agreed to:

[RELEASED ENTITY]

By: _____

Name: _____

Title: _____

Date: _____

SCHEDULE 1
PATENTS

[See Exhibit B]

EXHIBIT G**FORM OF DISMISSAL WITHOUT PREJUDICE FOR GRANTEE**

IN THE UNITED STATES DISTRICT COURT
FOR THE [] DISTRICT OF []

[]

Plaintiff,

v.

[], ET AL.,

Defendants.

CIVIL ACTION NO. []-CV-[]

JOINT MOTION TO DISMISS

WHEREAS, Plaintiff [] (“Plaintiff”) and Defendant [] (“[]”) have resolved Plaintiff’s claims for relief against [] and []’s counterclaims for relief against Plaintiff asserted in this case, for the present.

NOW, THEREFORE, Plaintiff and [], through their attorneys of record, request this Court to dismiss Plaintiff’s claims for relief against [] without prejudice and []’s claims, defenses or counterclaims for relief against Plaintiff without prejudice, and with all attorneys’ fees, costs of court and expenses borne by the party incurring same.

_____, 20____

/s/ _____

Respectfully submitted,

/s/ _____

ATTORNEY FOR PLAINTIFF

[]

ATTORNEY FOR DEFENDANT

[]

CONFIDENTIAL

IN THE UNITED STATES DISTRICT COURT
FOR THE [] DISTRICT OF []

[]

Plaintiff,

v.

[], ET AL.,

Defendants.

CIVIL ACTION NO. []-CV-[]

ORDER OF DISMISSAL WITHOUT PREJUDICE

On this day, Plaintiff [] (“Plaintiff”) and Defendant and Counterclaim-Plaintiff [] (“[]”) announced to the Court that they have resolved Plaintiff’s claims for relief against [] asserted in this case and []’s claims, defenses and/or counterclaims for relief against Plaintiff asserted in this case. Plaintiff and [] have therefore requested that the Court dismiss Plaintiff’s claims for relief against [] without prejudice and []’s claims, defenses and/or counterclaims for relief against Plaintiff without prejudice, and with all attorneys’ fees, costs and expenses taxed against the party incurring same. The Court, having considered this request, is of the opinion that their request for dismissal should be granted.

IT IS THEREFORE ORDERED that Plaintiff’s claims for relief against [] are dismissed without prejudice and []’s claims, defenses and/or counterclaims for relief against Plaintiff are dismissed without prejudice. IT IS FURTHER ORDERED that all attorneys’ fees, costs of court and expenses shall be borne by each party incurring the same.